Skip to content

NovoCure NVCR Others — Total long lived assets

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.7B-36.7%
Enterprise value$1.66B-36.3%
P/S2.5×-1.8×

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:NoncurrentAssets.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's others — total long lived assets.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's others — total long lived assets?
NovoCure (NVCR) reported others — total long lived assets of $18.8M in Q1 2026.
How has NovoCure's others — total long lived assets changed year-over-year?
NovoCure's others — total long lived assets increased by 26.1% year-over-year, from $14.91M to $18.8M.
What is the long-term trend for NovoCure's others — total long lived assets?
Over 4 years (2021 to 2025), NovoCure's others — total long lived assets has grown at a 103.1% compound annual growth rate (CAGR), from $4.12M to $70.09M.